• Cardiovascular events were the most common cause of death (54% of cases) in a large study of hospitalized patients with atrial fibrillation.
• Fatal stroke or fatal bleeding each accounted for 7% of all deaths.
• The strongest predictors of overall death were permanent atrial fibrillation, heart failure (whether with decreased or with preserved ejection fraction), previous bleeding and renal failure.
• Oral anticoagulant use was independently associated with a lower risk of all-cause mortality, cardiovascular mortality, and non-cardiovascular mortality.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT

INTRODUCTION
Atrial fibrillation is the most common sustained arrhythmia and significantly increases mortality and morbidity, and impairs quality of life. Strategies to reduce overall atrial fibrillation-related mortality are focused on the prevention of thromboembolism. Indeed, oral anticoagulation with the Vitamin K antagonists (VKA, eg. warfarin) significantly reduce stroke and systemic embolism by 64% compared to placebo or control, although all-cause mortality is also significantly reduced by 26% 1 . The development of non vitamin-K oral anticoagulants (NOACs) which are simpler to use, and at least as effective and safe as vitamin K antagonist (VKA) may provide additional reductions in morbidity and mortality in this population 2 .
However, patients with atrial fibrillation often have several cardiovascular risk factors, structural heart disease, and comorbidities, all of which can increase mortality [3] [4] [5] [6] [7] 
METHODS
We included all patients with a diagnosis of atrial fibrillation seen in the cardiology department in our institution between January 2000 and December 2010 8 . Atrial fibrillation was defined on the electrocardiogram by the replacement of consistent P waves by rapid oscillations or fibrillatory waves that vary in amplitude, shape, and timing, associated with an irregular, often rapid ventricular response. Patients' characteristics were obtained from the records of our institution's computerized codification system for each patient. Extensive information was collected on date of admission, discharge, diagnosis, clinical presentation, comorbidities, medication and subsequent hospitalization or outpatient visit. Patients entered into the study on their first cardiology encounter during the study period with atrial fibrillation. For each patient, the thromboembolic risk was estimated at the time of entry into the study using the CHA 2 None of the patients were treated with NOAC during this study period.
During follow-up, deaths from all causes and events of interest were recorded whenever they occurred in our institution, which includes a total of 4 hospitals covering all medical and surgical specialties. Our hospital covers an area of 4000 km 2 , and a population of 400.000 inhabitants and is the only public institution in the area. In addition, mortality data were obtained using a search Ethical review was therefore not required. Patient consent was not sought. The study was conducted retrospectively, patients were not involved in its conduct, and there was no impact on their care.
Statistical analysis
Patient characteristics are reported as percentages and the mean ± standard deviation (SD).
M A N U S C R I P T
A C C E P T E D 
Patient characteristics
Patients who died during follow-up were older, were more frequently with permanent atrial fibrillation and had higher CHA 2 DS 2 -VASc score, HASBLED score and SAMeTT 2 R 2 score (Table 1) .. Among patients with heart failure, 51% had ischemic etiology and among those with left ventricular ejection fraction measured in the 6 previous months with either echocardiography or angioscintigraphy, there were 34% with reduced left ventricular ejection fraction <40% and 24% with ejection fraction 40-49%. In patients with heart failure, 52% were treated with betablockers (59% in those with ejection fraction <40%, 57% in those with ejection fraction 40-49%
and 43% in those with ejection fraction ≥50%. Among patients who died during the follow-up,
there was a higher prevalence of patients with various cardiovascular comorbidities, as well as alcohol abuse and active smoking. The proportion of patients with coronary artery disease, heart failure (whether with decreased or preserved ejection fraction) and those with a left ventricular ejection fraction <40% was higher among the patients dead at the end of follow-up Non-use of antithrombotic therapy was higher, and the proportion of patients on VKA was lower, among those who died during follow-up. The proportion of patients on beta-blockers was higher among the patients alive at the end of follow-up.
Causes of death and impact of prescription of VKA
Among the 1,294 causes of death identified, 699 (54%) were cardiovascular and 552 (43%) noncardiovascular. Heart failure was the primary cause of cardiovascular deaths (29.2%) whereas infection (17.6%) was the primary cause of non-cardiovascular deaths ( Figure 1 , Table 2 ).
After adjustment for age, sex, characteristics of atrial fibrillation (permanent or non-permanent), comorbidities and treatments, the prescription of VKA was independently associated with a lower overall mortality, cardiovascular mortality and non-cardiovascular mortality (risk reduction of 38%, 40% and 40%) ( Table 3) . Among cardiovascular deaths, prescription of VKA was associated with a non-significantly lower risk of fatal stroke in our cohort. Central nervous system fatal hemorrhage was not independently linked with prescription of VKA. VKA use was also associated with a lower risk of vascular events such as fatal pulmonary embolism or fatal aortic syndrome.
Among non-cardiovascular death, prescription of VKA was independently associated with a higher risk of fatal trauma (245%). This higher risk was not significant for deaths from cerebral
trauma but was significant for other trauma-related deaths ( Table 3) .
Independent predictors of the main causes of death
Besides age and male gender, the presence of permanent atrial fibrillation, heart failure (whether with systolic dysfunction or with preserved ejection fraction, and with ischemic or non-ischemic etiology), previous major bleeding and renal failure were independently associated with an increase in the risk of overall mortality (35%, 78%, 42% and 79% respectively), cardiovascular mortality (43%, 129%, 46% and 93%) and non-cardiovascular mortality (21%, 45%, 40% and 50%) ( Table 4 ).
Death due to heart failure was independently associated with permanent atrial fibrillation, coronary artery disease, previous heart failure (whether with decreased or with preserved ejection fraction), previous acute coronary syndrome, renal failure or left bundle branch block. Of note, use of beta-blockers was associated with a 22% decrease in the risk of death related to heart failure. Death due to sudden cardiac death was independently associated with older age, history of heart failure (whether with decreased or with preserved ejection fraction), and renal failure ( Table 5 ).
There were more permanent atrial fibrillation patients who died due to a fatal stroke, and as expected, age and CHA 2 DS 2 -VASc scores were significant predictors of fatal stroke. For fatal bleeding, HASBLED score, age and renal failure were predictors on the unadjusted analysis, but only age was significant predictor for more fatal bleeds on adjustment. Patients with a prescription of VKA had lower risk of death from fatal bleeding ( Table 6) .
DISCUSSION
In our cohort, the three main causes of death were heart failure (29%), infections (18%) and cancer (12%), whilst stroke and hemorrhagic-related deaths each only contributed for approximately 7% of causes of death. Second, the presence of permanent atrial fibrillation, heart failure (whether with decreased or with preserved ejection fraction), previous bleeding and renal failure were all independently associated with an increase in the risk of all cause mortality, cardiovascular mortality and non-cardiovascular mortality. Third, oral anticoagulant use was independently associated with a lower risk of mortality.
Our work is the first to detail the causes of mortality and identified independent predictors of the main causes of death in a large population of unselected and well characterized patients with atrial fibrillation.
The identification of these predictors for the specific mode of death may help to develop effective targeted interventions in order to reduce overall atrial fibrillation-related mortality.
VKA use was independently associated with a decrease in overall mortality during follow-up, as was previously suggested for patients seen in randomized trials 1 . While 24% of patients who died did not receive thromboprophylaxis in our cohort, the distribution of causes of death in our cohort was different (with lower rates of cardiovascular deaths and fatal strokes) than that seen in the RE-LY analysis 14 . The latter was a selected clinical trial population in which all patients were receiving anticoagulant therapy.
Our work suggests that anticoagulation is perhaps not the only consideration amongst strategies
for the reduction of atrial fibrillation-related mortality, and we should also target comorbidities associated with atrial fibrillation. Indeed, we found that heart failure (whether with decreased or with preserved ejection fraction) increased risk of overall mortality (78%), cardiovascular mortality (129%), non-cardiovascular mortality (45%), heart failure-related mortality (178%) and sudden cardiac death (222%). These data are consistent with the RE-LY trial analysis, although a lower annual rate of death (3.8%) was seen 14 . Similarly, in the recent observational XANTUS study of atrial fibrillation patients treated with rivaroxaban, death occurred in 118 patients (yearly rate 1.9%) within the study treatment period, with the adjudicated cause of death due primarily to cardiovascular causes, mainly heart failure, followed by cancer 15 . Our findings clearly reflect the less selected 'real world' nature of our atrial fibrillation patients, given the annual rate of death was 5.5%.
In our cohort, only 52% of atrial fibrillation patients with heart failure (with decreased or with preserved ejection fraction) were treated with beta-blockers as in other studies 16 . We found that patients who died during follow-up had a significantly lower rate of prescription of beta-blockers.
Of note, beta-blocker use was independently associated with a decrease of 22% in the risk of heart failure-related mortality while there was no association with a lower risk of sudden death in our patients. This is consistent with another large study from the Danish nationwide cohort study 17 . However, a recent individual patient metaanalysis of trial data suggests that the effect of betablockers on outcome in HF patients with reduced systolic LVEF who have atrial fibrillation may be less than in those who have sinus rhythm 18 . Although the subject is currently debated, increasing the rate of patients with atrial fibrillation and heart failure treated according to guidelines remains crucial, particularly for those with systolic heart failure, in order to decrease mortality in contemporary populations 19 . Patients not using beta-blockers may also have Renal failure increases the morbidity, overall mortality and cardiovascular mortality in populations that it affects [20] [21] [22] [23] . Although deaths from renal failure-related death represented only 1.55% of all causes of death, renal failure also appeared to be a strongly associated with mortality amongst patients with atrial fibrillation. A similar finding was recently reported for atrial fibrillation patients dying in French hospitals, although there was no information on medication use 24 . After adjustment of potential confounding parameters, renal failure was independently associated with a higher risk of overall mortality (21%, which is consistent with the Danish Registry data on 132,372 patients with atrial fibrillation 25 ), as well as cardiovascular mortality (93 %), non-cardiovascular mortality (50%), heart failure-related death (124%) and sudden cardiac death (145%). The result on total mortality was also consistent with the Danish Registry data on 132,372 patients with atrial fibrillation, although this did not analyze the mode of death 25 . By contrast, renal failure was not an independent predictor of occurrence of a fatal stroke or fatal hemorrhage on multivariate analysis.
Permanent atrial fibrillation was independently associated with an increased risk of overall mortality, cardiovascular mortality, non-cardiovascular mortality, heart failure-related death and fatal stroke, as previously reported for some of this findings [26] [27] [28] [29] [30] . However, our analysis is to our knowledge one of the first to report how permanent atrial fibrillation might be related to the mode of death. Nonetheless, a strategy of using drugs for rhythm control has not been found to be superior to rate control 31 
Study limitations
Our study was observational and not a randomized study, but this gives it the benefit of being a less biased reflection of events in a population of consecutive patients with atrial fibrillation. One needs to interpret associations with caution, and not attempt to infer causation. Permanent atrial fibrillation could be an expression of patients comorbidities with a worse overall state including a worse prognosis. It is plausible that the patients on VKA were younger and healthier, hence tolerated VKA and they may have had lower mortality rate because they were healthier. This viewed as being somewhat higher than the rates reported for the general population in the United States (30.8%) 32 and in France (27.5%) 33 . As such, atrial fibrillation may not simply reflect cardiovascular ageing and would differ from general population trends.
CONCLUSION
In a large cohort of unselected patients with atrial fibrillation, the majority of deaths was not • Cardiovascular events were the most common cause of death (54% of cases) in a large study of hospitalized patients with atrial fibrillation.
